Tag: Celiac Disease Treatment Market – Global Celiac Disease Treatment Industry Size

  • Celiac Disease Market Growth Outlook From $0.86 Billion In 2026 To $1.26 Billion By 2030

    Celiac Disease Market Growth Outlook From $0.86 Billion In 2026 To $1.26 Billion By 2030

    Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

    #Celiac Disease Market Forecast: Value Set To Climb From $0.86 Billion To $1.26 Billion#_x000D_

    The celiac disease market has experienced rapid expansion in recent years. It is projected to increase from $0.78 billion in 2025 to $0.87 billion in 2026, at a compound annual growth rate (CAGR) of 10.3%. This historical growth can be attributed to heightened autoimmune disease awareness, advancements in diagnostics, broader adoption of dietary management, specialized hospital gastroenterology care, and active patient advocacy._x000D_

    _x000D_

    The celiac disease market size is predicted to undergo significant expansion in the upcoming years. It is projected to climb to $1.27 billion in 2030, showing a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period stems from developments in novel drugs, innovations in gluten-free foods, personalized dietary plans, early detection programs, and microbiome research. Notable trends for this period include an increasing adoption of gluten-free diets, the rise of packaged gluten-free products, the broadening of drug-based treatments, enhanced disease awareness and diagnosis, and a concentrated focus on microbiome-based therapies._x000D_

    _x000D_

    #Get A Free Sample Report With In-Depth Market Insights:#_x000D_

    https://thebusinessresearchcompany.com/sample_request?id=80265976&type=smp&name=Celiac%20Disease%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

    _x000D_

    #Celiac Disease Market Demand Drivers Opening New Revenue Streams#_x000D_

    The expanding field of personalized medicine is anticipated to propel the celiac disease market forward. This healthcare approach customizes medical care based on an individual’s unique genetic profile, surrounding environment, and lifestyle choices. The rising demand for personalized medicine is driven by the growing accessibility of genetic testing, which facilitates more accurate diagnoses and treatments specifically tailored to individual patient requirements. For celiac disease treatment, the growth of personalized medicine is supportive by enabling precise identification of genetic markers and individual immune responses, thereby leading to more targeted and effective management strategies for each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA authorized 16 personalized therapies in 2023 targeting rare diseases, representing an increase compared to the 6 approved in 2022. Therefore, the advancement of personalized medicine will boost the growth of the celiac disease market._x000D_

    _x000D_

    #Celiac Disease Market Segment Analysis And Revenue Potential#_x000D_

    The celiac disease market covered in this report is segmented – _x000D_

    _x000D_

    1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments_x000D_

    2) By Route Of Administration: Oral, Parenteral_x000D_

    3) By End Users: Hospitals, Homecare, Other End-Users_x000D_

    _x000D_

    Subsegments:_x000D_

    1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy_x000D_

    2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages_x000D_

    3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators_x000D_

    _x000D_

    #Celiac Disease Market Trends Powering Strategic Industry Growth#_x000D_

    Major companies in the celiac disease market are prioritizing the development of advanced solutions, such as anti-interleukin-15 (IL-15) antibodies, to alleviate tissue damage by curbing hyperactive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are specialized proteins designed to inhibit the function of the IL-15 cytokine, assisting in the control of immune system activity and inflammation. For instance, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, announced that the U.S. Food and Drug Administration had granted Fast Track status to TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This investigational monoclonal antibody is being developed for individuals with celiac disease who maintain a gluten-free diet. It operates by blocking interleukin-15 (IL-15), a molecule implicated in triggering the immune response that causes intestinal harm in celiac patients. The therapy is currently in a Phase 2a clinical trial to assess its safety and efficacy._x000D_

    _x000D_

    #Celiac Disease Market Key Players Shaping Industry Direction#_x000D_

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc. _x000D_

    _x000D_

    #View The Full Celiac Disease Market Report:#_x000D_

    https://thebusinessresearchcompany.com/report/celiac-disease-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

    _x000D_

    #Celiac Disease Market Regional Breakdown: Where Is Demand Concentrated?#_x000D_

    North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

    _x000D_

    #Reach Out To Our Team:#_x000D_

    _x000D_

    The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

    Americas: +1 310-496-7795_x000D_

    Asia: +44 7882 955267 & +91 8897263534_x000D_

    Europe: +44 7882 955267_x000D_

    Email us at: marketing@tbrc.info_x000D_

    _x000D_

    #Follow us on:#_x000D_

    _x000D_

    LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Celiac Disease Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Celiac Disease Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Celiac Disease Market Size Forecast: How Large Could The Market Become By 2030?

    The market for celiac disease has experienced rapid expansion in recent years. Projections indicate it will rise from $0.78 billion in 2025 to $0.87 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. This historical growth has been driven by heightened awareness of autoimmune conditions, advancements in diagnostic methods, the uptake of dietary management approaches, specialized gastroenterology services in hospitals, and the influence of patient advocacy efforts.

    The market for celiac disease is projected to experience significant expansion over the coming years. By 2030, it is anticipated to reach a valuation of $1.27 billion, driven by a compound annual growth rate (CAGR) of 10.0%. Key factors fueling this growth during the forecast period include the development of innovative drugs, advances in gluten-free food products, tailored nutritional approaches, early detection initiatives, and investigations into the microbiome. Prominent trends shaping this period encompass a growing preference for gluten-free diets, the increasing availability of packaged gluten-free items, the emergence of pharmaceutical therapies, heightened disease recognition and diagnostic rates, and a concentrated effort on microbiome-centered interventions.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    #Celiac Disease Market Growth Factors: Which Forces Are Supporting Market Expansion?

    The expansion of personalized medicine is anticipated to propel the celiac disease market forward. This healthcare approach tailors medical interventions to an individual’s genetic makeup, environment, and lifestyle. Its growing adoption is fueled by wider access to genetic testing, which facilitates more precise diagnoses and customized treatments for specific patient requirements. By enabling the accurate identification of genetic markers and unique immune responses, personalized medicine enhances celiac disease management through more effective and individualized strategies. For example, the Personalized Medicine Coalition, a US-based nonprofit, reported in February 2024 that the FDA approved 16 personalized therapies for rare diseases in 2023, up from 6 in 2022. Consequently, the rise of personalized medicine will drive growth in the celiac disease market.

    Celiac Disease Market Categorization By Product Type And Application

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    Celiac Disease Market Industry Trends: What Changes Are Reshaping Demand?

    Key players in the celiac disease market are concentrating on creating innovative therapies, including anti-interleukin-15 (IL-15) antibodies, aimed at minimizing tissue damage by curbing excessive immune cell activity. These anti-IL-15 antibodies are specialized proteins designed to block the IL-15 cytokine, thereby regulating immune responses and reducing inflammation. A notable example occurred in May 2025, when Teva Pharmaceutical Industries, headquartered in Israel, revealed that the U.S. Food and Drug Administration had awarded Fast Track designation to TEV-53408, an experimental anti-IL-15 antibody. This investigational monoclonal antibody is intended for celiac disease patients who adhere to a gluten-free diet. It works by inhibiting interleukin-15 (IL-15), a key molecule that triggers the immune response responsible for intestinal damage in individuals with celiac disease. Currently, the therapy is undergoing a Phase 2a clinical trial to assess its safety and efficacy.

    Celiac Disease Market Company Landscape And Strategic Competition

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Access The Complete Celiac Disease Market Report:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Celiac Disease Market Regional Analysis: Which Region Leads By Revenue?

    North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Advancements In Personalized Medicine Fueling The Growth Of The Market Due To Increasing Precision In Diagnosis And Treatment Is Supporting Development Across The Celiac Disease Market

    Advancements In Personalized Medicine Fueling The Growth Of The Market Due To Increasing Precision In Diagnosis And Treatment Is Supporting Development Across The Celiac Disease Market

    The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

    What Market Value Expansion Is Expected For The Celiac Disease Market Over The Forecast Period?

    The celiac disease market has seen substantial growth recently. It is projected to increase from $0.78 billion in 2025 to $0.87 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. This historical expansion can be attributed to several factors including greater awareness of autoimmune diseases, advancements in diagnostics, the uptake of dietary management strategies, comprehensive hospital gastroenterology care, and robust patient advocacy.

    The celiac disease market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $1.27 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by factors such as the development of new drugs, advancements in gluten-free food products, personalized nutrition approaches, improved early screening initiatives, and ongoing microbiome research. Key developments expected during this period include an increase in the adoption of gluten-free diets, the expansion of packaged gluten-free food options, the proliferation of drug-based treatments, enhanced awareness and diagnosis of the disease, and a greater emphasis on microbiome-focused therapies.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What Key Growth Drivers Are Influencing The Celiac Disease Market?

    The expansion of personalized medicine is projected to propel the growth of the celiac disease market going forward. This approach to healthcare customizes medical care based on an individual’s genetic profile, environment, and lifestyle. The demand for personalized medicine is increasing due to the growing availability of genetic testing, which facilitates more accurate diagnoses and treatments specifically tailored to individual patient needs. Its advancement supports celiac disease treatment by enabling precise identification of genetic markers and individual immune responses, thereby leading to more targeted and effective management strategies for each patient. For instance, in February 2024, the US-based nonprofit organization, Personalized Medicine Coalition, stated that the FDA authorized 16 personalized therapies in 2023 targeting rare diseases, representing a rise compared to the 6 approved in 2022. Consequently, the growth of personalized medicine will boost the growth of the celiac disease market.

    What Key Segment Areas Are Included In The Celiac Disease Market Assessment?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    Which Trends Are Expected To Shape The Celiac Disease Market?

    Leading companies in the celiac disease market are concentrating on developing advanced solutions, such as anti-interleukin-15 (IL-15) antibodies, to mitigate tissue damage by curbing hyperactive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are specialized proteins designed to inhibit the function of the IL-15 cytokine, thereby assisting in managing immune system responses and inflammation. For instance, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, announced that the U.S. Food and Drug Administration had granted Fast Track status for TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This is an investigational monoclonal antibody created for individuals with celiac disease who maintain a gluten-free diet. It operates by blocking interleukin-15 (IL-15), a molecule involved in triggering the immune reaction that causes intestinal harm in celiac patients. The therapy is currently being assessed in a Phase 2a clinical trial to determine its safety and effectiveness.

    Which Companies Are Influencing The Celiac Disease Market?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Access The Complete Celiac Disease Market Report:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    Which Region Has The Strongest Presence In The Celiac Disease Market?

    North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Celiac Disease Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    Browse Through More Reports Similar to the Global Celiac Disease Market 2026, By The Business Research Company

    Rare Diseases Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Disease Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Inflammatory Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Impact Of Increasing Rheumatoid Arthritis Prevalence On The Growth Of The Is Supporting Expansion In The Celiac Disease Market

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Projected Increase In Market Value Of The Celiac Disease Market During 2026–2030?

    In recent years, the market size for celiac disease has expanded quickly. Forecasts indicate a rise from $0.78 billion in 2025 to $0.87 billion in 2026, with a compound annual growth rate (CAGR) of 10.3%. The growth observed in past periods can be attributed to heightened autoimmune disease awareness, improved diagnostics, the adoption of dietary management strategies, comprehensive hospital gastroenterology care, and dedicated patient advocacy efforts.

    The celiac disease market size is anticipated to experience substantial growth over the coming years, with projections indicating it will reach $1.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This expansion during the forecast period is primarily driven by factors like novel drug development, gluten-free food innovation, personalized nutrition, early screening programs, and microbiome research. Significant trends identified for the forecast period comprise the rising adoption of gluten-free diets, an increase in packaged gluten-free foods, the expansion of drug-based therapies, enhanced disease awareness and diagnosis, and a focus on microbiome-based treatments.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What Primary Drivers Are Shaping The Celiac Disease Market?

    The expansion of personalized medicine is anticipated to propel the growth of the celiac disease market going forward. This healthcare approach customizes medical care based on an individual’s genetic profile, environment, and lifestyle. The demand for personalized medicine is increasing due to the wider availability of genetic testing, which allows for more accurate diagnoses and targeted treatments designed for individual patient needs. The development of personalized medicine supports celiac disease treatment by enabling precise identification of genetic markers and individual immune responses, leading to more targeted and effective management strategies for each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA authorized 16 personalized therapies in 2023 targeting rare diseases, a rise compared to the 6 approved in 2022. Consequently, the growth of personalized medicine will boost the growth of the celiac disease market.

    Which Segments Define The Celiac Disease Market Segment Structure?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    What Emerging Trends Are Seen In The Celiac Disease Market?

    Leading companies in the celiac disease market are focusing on developing advanced solutions, such as anti-interleukin-15 (IL-15) antibodies, to mitigate tissue damage by limiting excessive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are specialized proteins designed to inhibit the function of the IL-15 cytokine, thereby helping to regulate immune system activity and inflammation. For instance, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, announced that the U.S. Food and Drug Administration had granted Fast Track status for TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This is an investigational monoclonal antibody developed for individuals with celiac disease who continue to follow a gluten-free diet. It functions by blocking interleukin-15 (IL-15), a molecule implicated in triggering the immune response that leads to intestinal harm in celiac patients. The therapy is currently undergoing testing in a Phase 2a clinical trial to evaluate its safety and how effectively it works.

    Who Are The Established Players Within The Celiac Disease Market?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Get The Full Celiac Disease Market Report:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    Which Region Is The Leading Market For The Celiac Disease Market?

    North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Celiac Disease Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    Browse Through More Reports Similar to the Global Celiac Disease Market 2026, By The Business Research Company

    Rare Diseases Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Disease Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Inflammatory Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Personalized Medicine Advancements Driving Growth in the Celiac Disease Market

    Personalized Medicine Advancements Driving Growth in the Celiac Disease Market

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Valuation Is Forecasted For The Celiac Disease Market By 2030 Starting From Its 2026 Size?

    The celiac disease market size has experienced rapid growth in recent years. It is projected to expand from $0.78 billion in 2025 to $0.87 billion in 2026, driven by a compound annual growth rate (CAGR) of 10.3%. The historical increase can be ascribed to factors such as greater autoimmune disease awareness, enhancements in diagnostics, the adoption of dietary management, specialized hospital gastroenterology care, and active patient advocacy.

    The celiac disease market is anticipated to experience robust expansion in the upcoming years. Its value is set to reach $1.27 billion by 2030, progressing at a compound annual growth rate (CAGR) of 10.0%. This projected growth can be ascribed to advancements in novel drug development, innovation in gluten-free food products, personalized nutrition strategies, the implementation of early screening programs, and ongoing microbiome research. Significant developments expected during this forecast period encompass the increasing embrace of gluten-free diets, the rise in packaged gluten-free foods, the expansion of drug-based therapies, enhanced disease awareness and diagnosis, and a concentrated focus on treatments based on the microbiome.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What Primary Drivers Are Shaping The Development Of The Celiac Disease Market?

    The expanding scope of personalized medicine is anticipated to fuel the celiac disease market’s advancement. This healthcare approach tailors medical interventions to an individual’s unique genetic makeup, environmental factors, and lifestyle. The increasing availability of genetic testing is boosting the demand for personalized medicine, facilitating more precise diagnoses and therapies customized for each patient. For celiac disease treatment, the rise of personalized medicine enables the accurate identification of genetic markers and individual immune responses, leading to more focused and effective management strategies for patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA approved 16 personalized therapies for rare diseases in 2023, marking an increase from the 6 approvals in 2022. Consequently, the progress in personalized medicine is poised to enhance the growth of the celiac disease market.

    Which Segment Categories Define The Celiac Disease Market?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    What Major Market Trends Are Driving Changes In The Celiac Disease Market?

    Leading companies within the celiac disease market are concentrating on developing advanced solutions, such as anti-interleukin-15 (IL-15) antibodies, to mitigate tissue damage by restricting overactive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are specialized proteins designed to inhibit the function of the IL-15 cytokine, thereby helping to regulate immune system activity and inflammation. For instance, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, announced that the U.S. Food and Drug Administration had granted Fast Track status for TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This investigational monoclonal antibody is being developed for individuals with celiac disease who continue to follow a gluten-free diet. It functions by blocking interleukin-15 (IL-15), a molecule implicated in triggering the immune response that leads to intestinal harm in celiac patients. The therapy is currently being evaluated in a Phase 2a clinical trial to assess its safety and efficacy.

    Who Are The Top Companies Competing In The Celiac Disease Market?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Read the full celiac disease market report here:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    How Does The Celiac Disease Market Perform Across Major Global Regions?

    North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Celiac Disease Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24497&type=smp

    Browse Through More Reports Similar to the Global Celiac Disease Market 2026, By The Business Research Company

    Rare Diseases Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Disease Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Inflammatory Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Personalized Medicine Advancements Driving Growth in the Celiac Disease Market

    Personalized Medicine Advancements Driving Growth in the Celiac Disease Market

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Valuation Is Forecasted For The Celiac Disease Market By 2030 Starting From Its 2026 Size?

    The celiac disease market size has experienced rapid growth in recent years. It is projected to expand from $0.78 billion in 2025 to $0.87 billion in 2026, driven by a compound annual growth rate (CAGR) of 10.3%. The historical increase can be ascribed to factors such as greater autoimmune disease awareness, enhancements in diagnostics, the adoption of dietary management, specialized hospital gastroenterology care, and active patient advocacy.

    The celiac disease market is anticipated to experience robust expansion in the upcoming years. Its value is set to reach $1.27 billion by 2030, progressing at a compound annual growth rate (CAGR) of 10.0%. This projected growth can be ascribed to advancements in novel drug development, innovation in gluten-free food products, personalized nutrition strategies, the implementation of early screening programs, and ongoing microbiome research. Significant developments expected during this forecast period encompass the increasing embrace of gluten-free diets, the rise in packaged gluten-free foods, the expansion of drug-based therapies, enhanced disease awareness and diagnosis, and a concentrated focus on treatments based on the microbiome.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What Primary Drivers Are Shaping The Development Of The Celiac Disease Market?

    The expanding scope of personalized medicine is anticipated to fuel the celiac disease market’s advancement. This healthcare approach tailors medical interventions to an individual’s unique genetic makeup, environmental factors, and lifestyle. The increasing availability of genetic testing is boosting the demand for personalized medicine, facilitating more precise diagnoses and therapies customized for each patient. For celiac disease treatment, the rise of personalized medicine enables the accurate identification of genetic markers and individual immune responses, leading to more focused and effective management strategies for patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA approved 16 personalized therapies for rare diseases in 2023, marking an increase from the 6 approvals in 2022. Consequently, the progress in personalized medicine is poised to enhance the growth of the celiac disease market.

    Which Segment Categories Define The Celiac Disease Market?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    What Major Market Trends Are Driving Changes In The Celiac Disease Market?

    Leading companies within the celiac disease market are concentrating on developing advanced solutions, such as anti-interleukin-15 (IL-15) antibodies, to mitigate tissue damage by restricting overactive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are specialized proteins designed to inhibit the function of the IL-15 cytokine, thereby helping to regulate immune system activity and inflammation. For instance, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, announced that the U.S. Food and Drug Administration had granted Fast Track status for TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This investigational monoclonal antibody is being developed for individuals with celiac disease who continue to follow a gluten-free diet. It functions by blocking interleukin-15 (IL-15), a molecule implicated in triggering the immune response that leads to intestinal harm in celiac patients. The therapy is currently being evaluated in a Phase 2a clinical trial to assess its safety and efficacy.

    Who Are The Top Companies Competing In The Celiac Disease Market?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Read the full celiac disease market report here:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    How Does The Celiac Disease Market Perform Across Major Global Regions?

    North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Celiac Disease Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24497&type=smp

    Browse Through More Reports Similar to the Global Celiac Disease Market 2026, By The Business Research Company

    Rare Diseases Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Disease Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Inflammatory Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Celiac Disease Market Anticipated to Record Steady Gains, Advancing to $1.27 Billion by 2030

    Celiac Disease Market Anticipated to Record Steady Gains, Advancing to $1.27 Billion by 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the celiac disease market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Celiac Disease Market in 2030?

    The celiac disease market has experienced substantial expansion in recent years. Projections indicate its value will increase from $0.78 billion in 2025 to $0.87 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this expansion has been driven by factors such as increased autoimmune disease awareness, advancements in diagnostics, broader adoption of dietary management, enhanced hospital gastroenterology care, and active patient advocacy.

    The celiac disease market is projected to experience substantial expansion in the coming years, reaching $1.27 billion by 2030, progressing at a compound annual growth rate (CAGR) of 10.0%. This anticipated growth is driven by factors such as the development of new drugs, advancements in gluten-free food products, tailored nutrition approaches, the implementation of early screening initiatives, and ongoing microbiome research. Key trends during this period are expected to encompass an increase in the adoption of gluten-free diets, the expanding market for packaged gluten-free foods, the broadening of drug-centric therapies, enhanced disease awareness and diagnostic efforts, and a strong emphasis on microbiome-focused treatments.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What Drivers Are Influencing Production Trends In The Celiac Disease Market?

    The future expansion of personalized medicine is projected to propel the advancement of the celiac disease market. This medical strategy tailors healthcare solutions according to an individual’s unique genetic makeup, environmental factors, and lifestyle choices. A growing demand for personalized medicine stems from the wider accessibility of genetic testing, facilitating more precise diagnoses and therapeutic interventions customized for each patient’s requirements. The advancement of personalized medicine aids celiac disease treatment by enabling the accurate identification of genetic indicators and specific immune reactions, resulting in more focused and efficacious management plans for individual patients. An illustrative example is that in February 2024, data from the Personalized Medicine Coalition, a US-based nonprofit entity, showed that the FDA granted authorization to 16 personalized therapies in 2023 for rare diseases, marking an increase from the 6 approved in 2022. Consequently, the expansion of personalized medicine is set to invigorate the celiac disease market’s growth.

    Which Segments Are Gaining Traction In The Celiac Disease Market?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    2) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    3) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    How Are New Market Trends Shaping The Landscape Of The Celiac Disease Market?

    Leading companies within the celiac disease market are concentrating on creating sophisticated treatments, including anti-interleukin-15 (IL-15) antibodies, aimed at lessening tissue damage by moderating overactive immune cell function. These anti-interleukin-15 (IL-15) antibodies are specialized proteins designed to impede the IL-15 cytokine’s action, thereby assisting in the regulation of immune system activity and inflammation. As an illustration, Teva Pharmaceutical Industries, an Israeli pharmaceutical firm, declared in May 2025 that the U.S. Food and Drug Administration had designated TEV-53408, an experimental anti-interleukin-15 (IL-15) antibody, with Fast Track status. This investigational monoclonal antibody is being developed for celiac disease patients who adhere to a gluten-free diet. Its mode of action involves obstructing interleukin-15 (IL-15), a molecule crucial in initiating the immune response that results in intestinal damage for individuals with celiac disease. The treatment is presently undergoing assessment in a Phase 2a clinical trial to determine both its safety and effectiveness.

    Who Are The Prominent Global Companies Shaping The Celiac Disease Market Landscape?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    Which Geographic Areas Are Emerging As Strong Markets For The Celiac Disease Market?

    North America was the largest region in the celiac disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Celiac Disease Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24497&type=smp

    Browse Through More Reports Similar to the Global Celiac Disease Market 2026, By The Business Research Company

    Rare Diseases Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Disease Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Inflammatory Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Celiac Disease Market Size Forecast: Revenue and CAGR by 2029

    Celiac Disease Market Size Forecast: Revenue and CAGR by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Is The Global Market Value Of The Celiac Disease Industry In 2025?

    The celiac disease market size has seen significant expansion in recent years. It is anticipated to increase from $0.71 billion in 2024 to $0.78 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.4%. The factors contributing to this growth in previous periods include the escalating prevalence of celiac disease, heightened public knowledge of gluten-related conditions, increased financial support for autoimmune disease research, a rise in occurrences of food allergies and sensitivities, and a greater emphasis on health among consumers.

    The celiac disease market is projected to experience substantial expansion over the upcoming years. This market is set to reach a valuation of $1.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.1%. The anticipated growth during this period is driven by factors such as the increasing call for personalized medicine, the broadening of healthcare infrastructure, a greater need for nutritional counseling services, an increase in pediatric diagnosis rates, and an emphasis on early life screening and preventative measures. Key developments anticipated in the forecast period encompass the wider availability of diagnostic testing, progress in genetic testing technologies, enhanced screening protocols within primary care, technological breakthroughs in ELISA and serological testing, and the increasing uptake of non-invasive diagnostic methods.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What Are The Top Growth Drivers Impacting The Celiac Disease Market Outlook?

    The celiac disease market is anticipated to expand due to the advancement of personalized medicine. This healthcare method tailors treatments to an individual’s unique genetic makeup, environmental factors, and lifestyle choices. The demand for personalized medicine is increasing, driven by wider access to genetic testing, which allows for more precise diagnoses and therapies specifically designed for each patient. In the context of celiac disease treatment, personalized medicine facilitates the exact identification of genetic markers and distinct immune responses, resulting in more focused and efficient management plans for every patient. As an illustration, the Personalized Medicine Coalition, a US-based nonprofit, reported in February 2024 that the FDA cleared 16 personalized therapies for rare diseases in 2023, representing an increase from the 6 approved in 2022. Consequently, the expansion of personalized medicine is set to propel the celiac disease market forward.

    What Are The Key Segments In The Celiac Disease Market?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Infliximab, Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Infliximab: Biosimilar Infliximab, Branded Infliximab, Intravenous Administration, Hospital-Based Usage, Off-Label Use In Refractory Celiac Disease,

    2) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    3) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    4) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    Which Market Trends Are Creating New Opportunities In The Celiac Disease Industry?

    Leading companies within the celiac disease market are prioritizing the creation of advanced interventions, such as anti-interleukin-15 (IL-15) antibodies, to mitigate tissue damage by reining in excessive immune cell activity. These anti-interleukin-15 (IL-15) antibodies are specialized proteins designed to inhibit the function of the IL-15 cytokine, thereby assisting in the regulation of immune system activity and inflammation. For example, in May 2025, Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, publicized that the U.S. Food and Drug Administration had granted Fast Track status to TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This particular investigational monoclonal antibody is being developed for individuals with celiac disease who continue to follow a gluten-free diet. Its mode of action involves blocking interleukin-15 (IL-15), a molecule instrumental in initiating the immune response that results in intestinal harm for celiac patients. The therapy is presently undergoing a Phase 2a clinical trial to assess both its safety and effectiveness.

    Who Are The Core Companies Influencing The Celiac Disease Market Landscape?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    How Is Celiac Disease Market Demand Varying Across Different Regions?

    North America was the largest region in the celiac disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Celiac Disease Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=24497&type=smp

    Browse Through More Reports Similar to the Global Celiac Disease Market 2025, By The Business Research Company

    Rare Diseases Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

    Rare Disease Diagnostics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

    Rare Inflammatory Disease Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Future Projections: Celiac Disease Market to Reach $1.15 Billion by 2029 at 10.1% CAGR

    Future Projections: Celiac Disease Market to Reach $1.15 Billion by 2029 at 10.1% CAGR

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What CAGR Is Anticipated for the Celiac Disease Market Through 2029?

    The market size for celiac disease has witnessed a significant expansion in the past few years. The market is set to surge from $0.71 billion in 2024 to $0.78 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth during the historic period include an increased incidence of celiac disease, greater awareness of disorders related to gluten, enhanced research funding towards autoimmune diseases, a spike in food allergies and sensitivities, and a heightened level of health consciousness among consumers.

    In the coming years, the celiac disease market is expected to undergo swift growth, reaching a size of $1.15 billion in 2029, with a compound annual growth rate of 10.1%. The growth anticipated in this forecast period can be accredited to a surge in demand for custom-made medicine, improvements in healthcare infrastructure, a growing need for nutritional counseling services, an increase in child diagnosis rates, and emphasis on early childhood screening and prevention. Notable trends within this period are the presence of diagnostic testing, developments in genetic testing technologies, enhanced primary care screening protocols, technological advancements in ELISA and serological testing, and the use of non-invasive diagnostic methods.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What Market Forces Are Driving The Celiac Disease Sector In 2025 And Beyond?

    The evolution of personalized medicine is anticipated to catalyze the expansion of the celiac disease market in the future. Tailoring healthcare to align with a person’s genetic makeup, surroundings, and lifestyle defines personalized medicine. The surge in demand for this kind of tailored medicine is caused by the advancements in genetic testing, which paves the way for more precise diagnoses and treatments designed to cater to unique patient needs. Personalized medicine boosts celiac disease treatment by providing exact identification of genetic indicators and individual immune responses, which results in more specific and effective treatment strategies for each patient. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the US, reported that the FDA had greenlit 16 personalized therapies in 2023, focusing on rare diseases, which signified an increase from the 6 approved in 2022. Consequently, the evolution of personalized medicine will stimulate the expansion of the celiac disease market.

    How Is The Global Celiac Disease Market Categorized By Segments?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Infliximab, Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Infliximab: Biosimilar Infliximab, Branded Infliximab, Intravenous Administration, Hospital-Based Usage, Off-Label Use In Refractory Celiac Disease,

    2) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    3) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    4) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    What Long-Term Trends Are Likely To Affect The Celiac Disease Market?

    Leading firms in the celiac disease market are concentrating on the creation of innovative solutions, such as anti-interleukin-15 (IL-15) antibodies, which help in mitigating tissue injury by controlling excessive immune cell activity. Anti-interleukin-15 (IL-15) antibodies, special types of proteins, impede the functionality of IL-15 cytokine, thus putting a check on the activity of the immune system and inflammation. For instance, in May 2025, the U.S. Food and Drug Administration gave Fast Track status to TEV-53408, an experimental anti-interleukin-15 (IL-15) antibody, launched by Teva Pharmaceutical Industries, a pharmaceutical corporation based in Israel. This exploratory monoclonal antibody, designed especially for individuals with celiac disease who continue to maintain a gluten-free diet, operates by impeding interleukin-15 (IL-15), a substance that sets off the immune reaction leading to intestinal damage in patients with celiac disease. Currently, the safety and efficacy of this treatment option are being examined in a Phase 2a clinical trial.

    Which Firms Are Considered Leaders In The Celiac Disease Market Space?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    Get The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    What Role Do Regional Policies And Investments Play In Celiac Disease Market Expansion?

    North America was the largest region in the celiac disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24497&type=smp

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Celiac Disease Market Trends Report 2025 – For Business Development and Strategy Teams

    Celiac Disease Market Trends Report 2025 – For Business Development and Strategy Teams

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Forecast for the Celiac Disease Market Growth in 2025?

    In the last few years, the market size for celiac disease has seen significant expansion. It is projected to accelerate from $0.71 billion in 2024 to $0.78 billion in 2025, marking a compound annual growth rate (CAGR) of 10.4%. This growth during the historical period is due to several factors, including a surge in celiac disease incidences, heightened knowledge about disorders linked to gluten, more funding allocated for autoimmune diseases research, the rise in food allergy cases and sensitivities, and an increased focus on health among consumers.

    What Is the Forecast for the Celiac Disease Market Size Through 2029?

    The market for celiac disease is set for swift expansion in the upcoming years, with projections suggesting it will surge to $1.15 billion by 2029, with a compound annual growth rate (CAGR) of 10.1%. Factors contributing to this predicted growth in the forecast period are the escalating demand for personalized medicine, strengthened healthcare facilities, increased needs for dietetic counseling services, and higher rates of pediatric diagnosis. Other proactive steps towards early detection and prevention are also key contributors. Noteworthy trends for the forecast period comprise the accessibility of diagnostic tests, advancements in the field of genetic testing, enhanced primary care screening protocols, cutting-edge innovations in ELISA and serological testing, and the embrace of non-evasive diagnostic methodologies.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

    What are the Key Market Players in Celiac Disease Market and How They’re Evolving?

    Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

    What Are the Primary Growth Drivers in the Celiac Disease Market?

    The expansion of the celiac disease market is anticipated to be propelled by the rise in personalized medicine. Personalized healthcare, which individualizes medical treatment based on one’s genetic makeup, environment, and lifestyle, is at the heart of this. The surge in genetic testing availability, which makes for more precise diagnoses and treatments tailored to each patient, is heightening the appeal of personalized medicine. It aids in the treatment of celiac disease by facilitating the exact identification of genetic markers and personal immune responses, resulting in more specific and effective management techniques for each patient. For example, the US-based nonprofit organization, the Personalized Medicine Coalition, reported in February 2024 that the FDA sanctioned 16 personalized therapies aimed at rare diseases in 2023, an increase from the 6 that were approved in 2022. Therefore, the rise in personalized medicine is set to stimulate the expansion of the celiac disease market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24497&type=smp

    What Are the Leading Segments in the Global Celiac Disease Industry?

    The celiac disease market covered in this report is segmented –

    1) By Treatment: Infliximab, Larazotide Acetate, Gluten Free Diet, Other Treatments

    2) By Route Of Administration: Oral, Parenteral

    3) By End Users: Hospitals, Homecare, Other End-Users

    Subsegments:

    1) By Infliximab: Biosimilar Infliximab, Branded Infliximab, Intravenous Administration, Hospital-Based Usage, Off-Label Use In Refractory Celiac Disease,

    2) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

    3) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

    4) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

    What Are the Key Market Trends in the Celiac Disease Industry?

    Leading corporations in the celiac disease sector are making strides in producing sophisticated solutions like anti-interleukin-15 (IL-15) antibodies, designed to prevent tissue harm by curbing the heightened activity of the immune cells. These antibodies are specialized proteins that hinder the IL-15 cytokine’s functionality, thereby keeping a check on the immune activity and inflammation. Notably, in May 2025, Teva Pharmaceutical Industries, a pharmaceutical firm based in Israel, reported that the U.S. Food and Drug Administration had allocated Fast Track status to its under-investigation anti-IL-15 antibody, TEV-53408. This investigational monoclonal antibody, targeted for individuals suffering from celiac disease who persist with a gluten-free diet, acts by obstructing IL-15, an element instrumental in igniting the immune response consequential in intestinal damage in sufferers of celiac disease. Currently, the treatment’s safety and effectiveness are under scrutiny in a Phase 2a clinical trial.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

    What Is the Regional Outlook for the Celiac Disease Market?

    North America was the largest region in the celiac disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24497

    This Report Delivers Insight On:

    1. How big is the celiac disease market, and how is it changing globally?

    2. Who are the major companies in the celiac disease market, and how are they performing?

    3. What are the key opportunities and risks in the celiac disease market right now?

    4. Which products or customer segments are growing the most in the celiac disease market?

    5. What factors are helping or slowing down the growth of the celiac disease market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model